 SOUTH PLAINFIELD, N.J., April 14, 2021 PRNewswire -- PTC Therapeutics, Inc. NASDAQ: PTCT today introduced a new no-charge, patient-initiated testing program in the United States for individuals who have symptoms consistent with, or a diagnosis of, cerebral palsy CP with no evidence of brain injury. 